Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
MSD Seeks Japan Nod for 21-Valent Pneumococcal Jab for Adults
MSD said on August 9 that it has filed a new drug application in Japan for its 21-valent pneumococcal conjugate vaccine specifically designed for adults. The new shot provides protection against 21 Streptococcus pneumoniae serotypes that cause many cases of…
To read the full story
BUSINESS
- Ultomiris, Soliris Bolster Labels for gMG in Japan: Alexion
April 3, 2025
- Shionogi Grants Cefiderocol Rights to Clinigen Unit in Australia/New Zealand
April 3, 2025
- Cheplapharm Completes Tarceva Transfer, Announces Hydrea Acquisition in Japan
April 3, 2025
- Boehringer Will Wait and See Impact of Tariffs, FDA Layoffs: CEO
April 3, 2025
- Alper Alptekin Becomes Japan President of Organon
April 2, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…